CervoMed Inc. (CRVO) stock
CRVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$1.50−0.17 (-10.18%)
Close on Nov 17, 2026Market cap $22.68MP/E –Yield –
CervoMed operating margin
Operating margin is operating income as a percentage of revenue.
CervoMed's operating margin for the twelve months ending Jun 30, 2026 was -9407.0%. For fiscal 2025 it was -706.2%, against -187.2% the year before. The highest annual figure on record is -109.3% in fiscal 2023.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -706.2% | −519.0 |
| FY2024 | Dec 31, 2024 | -187.2% | −77.8 |
| FY2023 | Dec 31, 2023 | -109.3% | +17746.2 |
| FY2013 | Dec 31, 2013 | -17855.5% | −14707.2 |
| FY2012 | Dec 31, 2012 | -3148.3% | −268.4 |
| FY2011 | Dec 31, 2011 | -2879.9% | +16122.7 |
| FY2010 | Dec 31, 2010 | -19002.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -95479.2% | −95144.3 |
| Q3 FY2025 | Sep 30, 2025 | -2493.8% | −2215.6 |
| Q2 FY2025 | Jun 30, 2025 | -376.4% | −285.3 |
| Q1 FY2025 | Mar 31, 2025 | -276.6% | −166.0 |
| Q4 FY2024 | Dec 31, 2024 | -334.9% | −235.3 |
| Q3 FY2024 | Sep 30, 2024 | -278.2% | −102.9 |
| Q2 FY2024 | Jun 30, 2024 | -91.1% | −19.5 |
| Q1 FY2024 | Mar 31, 2024 | -110.6% | −9.2 |
| Q4 FY2023 | Dec 31, 2023 | -99.6% | – |
| Q3 FY2023 | Sep 30, 2023 | -175.2% | – |
| Q2 FY2023 | Jun 30, 2023 | -71.6% | – |
| Q1 FY2023 | Mar 31, 2023 | -101.3% | – |
See a number that looks wrong?